Nivolumab
Anti-PD-1 antibodies
A PD-1 inhibitor used in lung cancer, stomach cancer, and several other malignancies.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
- Generic name
- nivolumab
- Marketed brand names
- Opdivo
- Route
- Intravenous infusion
- Drug class
- Anti-PD-1 antibodies
Registration status
Registration status and availability in Indonesia must be confirmed directly with the health facility or authorized distributor. This page is not a source of marketing approval status.
Not a marketing-authorisation source
TanyaKanker does not state a drug's marketing approval status in Indonesia. Confirm official status only through a healthcare facility, BPOM, or an authorised distributor.
Access considerations
- Availability may vary between health facilities and changes over time.
- Funding pathway (insurance, patient access program, or self-directed) needs to be confirmed.
- Prices are not listed because they cannot be verified responsibly.
What needs verification
- Indications approved in the country where the drug is used.
- Compliance with the patient's latest biological marker examination results.
- Plan to monitor side effects and interactions with other drugs being used.
Related
Sources
- NCI Drug Dictionary(lembaga)
Studies related to this drug marker
NCT06170788Phase 3Immunotherapy
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Lung Cancer | biomarker: PD-L1 | Immunotherapy, Perawatan suportif dan paliatif
United States, Argentina, Australia +23220 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06170788Not verified
NCT06203600Phase 2 / Phase 3Combination regimen
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Stomach Cancer | biomarker: PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States375 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker PD-L1, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06203600Not verified
NCT05920356Phase 3Combination regimen
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Lung Cancer | biomarker: KRAS, PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States, Argentina, Australia +35421 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05920356Not verified
NCT06119581Phase 3Immunotherapy
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Lung Cancer | biomarker: KRAS, PD-L1 | Immunotherapy, Chemotherapy
United States, Australia, Austria +26415 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06119581Not verified
Request cost and access questions
We prepare cost and availability questions that need direct confirmation from a facility.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- MSI / MMR
Biomarker
Reason: Targets this marker
- PD-L1
Biomarker
Reason: Targets this marker
- Immunotherapy
Treatment category
Reason: Uses this drug
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Clinical trial
Reason: Uses this drug
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Clinical trial
Reason: Uses this drug
- Gastric cancer after chemotherapy no longer gives results
Decision situation
Reason: Related to this page
To check
- Cost and access questions
Tool
Reason: Prepare questions to ask a facility
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.